Notwithstanding encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from PBMs. The companies are frequently https://theogdtn101051.collectblogs.com/86689640/company-s-drug-faces-is-encountering-pharmacy-benefit-manager-challenges-a-review-of-reimbursement-battles